India: Indian Patent Office rejects application under Section 3(d) of the Indian Patent Act

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

India: Indian Patent Office rejects application under Section 3(d) of the Indian Patent Act

The Indian Patent Office vide order dated November 8 2017 has rejected patent application 6647/ DELNP/2007 for lack of inventive step and for non-patentable subject matter under Section 3(d) of the Indian Patent Act. The invention claimed in the application was directed to a composition comprising a monoclonal antibody (IgG2), a chelating agent, histidine buffer, and optionally, a surfactant and/or a tonicity agent. The applicant claimed enhanced stability of the antibody in the composition.

This article focuses on the rejection under Section 3(d) of the act which, among others, excludes from patentability "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance". The provision further includes an explanation which states that "for the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy". The moot question here is under what circumstances a claim for a composition can fall under the purview of Section 3(d) of the act as being a discovery of a new form of a known substance requiring enhanced efficacy to overcome the same.

The controller proceeded to reject the claims of the application under Section 3(d) of the act on the basis that the claimed composition is directed to a stable pharmaceutical composition of known monoclonal anti -CTLA-4 antibody 11.2.1 including the antibody, ticilimumab™ with already known components/pharmaceutical excipients such as EDTA, histidine buffer, trehalose, polysorbate 80. The controller also held that the role and effect of EDTA as chelating agent and antioxidant histidine as buffer on stability of antibody composition are known in the prior art. The controller thus held that the claimed invention constitutes use of known compounds in making pharmaceutical compositions of known antibodies and standardising the concentration of known components in a composition to impart stability to the composition, while showing no effect on efficacy of claimed antibodies. It is therefore not patentable under Section 3(d) of the act.

It is relevant to note that although the controller appears to have identified the known substance as the antibodies, the controller has failed to establish how the claimed composition constitutes "the mere discovery of a new form of a known substance". The controller failed to establish how the claimed composition constitutes one of the forms of the known substance set out in the explanation to Section 3(d) of the act. Further, the controller also failed to identify the known efficacy of the known substance.

Given that the claims of the application are directed to a composition, the only possible new form, as provided in the explanation to Section 3(d) of the act, in which the claims of the application, if at all, may fall is combinations. It is relevant to note that the Intellectual Property Appellate Board (IPAB) has previously interpreted the term combinations under the explanation to Section 3(d) of the act to only mean a combination of two or more of the derivatives mentioned in the explanation or combination of one or more of the derivatives with the known substance. The order has neither identified the known substance nor the specific category in the explanation to Section 3(d) in which the claimed composition falls.

The controller, without discharging the burden to establish the applicability of Section 3(d) of the act with respect to the composition claims of the application, shifted the burden onto the applicant to prove enhanced efficacy. It is also interesting to note that the hearing in this case took place on December 14 2011, but the order was passed on November 8 2017, nearly six years after the hearing which is unusually long.

Parthasarathy

R Parthasarathy

Lakshmi Kumaran & Sridharan

B6/10 Safdarjung Enclave

New Delhi 110029, India

Tel: +91 11 41299800

Fax: +91 11 41299899

vlakshmi@lakshmisri.com

www.lslaw.in

more from across site and SHARED ros bottom lb

More from across our site

Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Gift this article